Optimizing Intensive Chemotherapy Management in Secondary AML Through Academic Community Collaboration - Episode 3
The Role of Molecular and Cytogenetic Testing in Secondary AML
Panelists discuss how comprehensive molecular and cytogenetic testing at diagnosis is crucial for accurate risk stratification, treatment selection, and prognostication in secondary acute myeloid leukemia (AML), while acknowledging the challenges of obtaining timely results, especially in community settings.
Video content above is prompted by the following:
- Please discuss the importance of molecular and cytogenetic testing at diagnosis.
- Please highlight typical turnaround time in getting these results.
- Describe how the test results impact disease management.
- What challenges are often faced in the community setting when it comes to getting molecular and cytogenetic test results in a timely manner?
- How do you handle situations when you are waiting for molecular test results?
- In which scenarios do you initiate treatment while awaiting results?
Related Content:
